Ignite Creation Date:
2024-05-05 @ 9:18 PM
Last Modification Date:
2024-10-26 @ 10:02 AM
Study NCT ID:
NCT00851838
Status:
COMPLETED
Last Update Posted:
2019-06-25
First Post:
2009-02-25
Brief Title:
L-Carnitine as an Osmo-metabolic Agent for Peritoneal Dialysis
Sponsor:
Iperboreal Pharma Srl
Organization:
Iperboreal Pharma Srl
Study Overview
Official Title:
Phase 2 Study of Dialysis Efficiency and Tolerability of Peritoneal Dialysis Solution Containing Glucose Plus L-Carnitine in APD Automated Peritoneal Dialysis Treated Uremic Patients
Status:
COMPLETED
Status Verified Date:
2013-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A major challenge of peritoneal dialysis PD therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration UF profile Study hypothesis is to evaluate the possibility to formulate PD solutions containing L-carnitine as an osmotic agent to partially replace glucose
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None